IRIS
BARCHIESI, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.990
EU - Europa 3.868
AS - Asia 2.866
SA - Sud America 941
AF - Africa 165
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 3
Totale 15.840
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.886
SG - Singapore 997
UA - Ucraina 777
BR - Brasile 759
RU - Federazione Russa 463
IE - Irlanda 457
CN - Cina 449
TR - Turchia 442
DE - Germania 438
IT - Italia 428
SE - Svezia 381
VN - Vietnam 343
DK - Danimarca 283
HK - Hong Kong 262
FI - Finlandia 198
GB - Regno Unito 182
KR - Corea 155
FR - Francia 130
CI - Costa d'Avorio 95
AR - Argentina 80
CA - Canada 52
IN - India 48
MX - Messico 39
EC - Ecuador 32
ID - Indonesia 27
ZA - Sudafrica 27
BD - Bangladesh 26
NL - Olanda 26
IR - Iran 24
AT - Austria 22
PL - Polonia 22
PY - Paraguay 20
BE - Belgio 15
JP - Giappone 14
MA - Marocco 14
CL - Cile 13
CO - Colombia 13
IQ - Iraq 13
ES - Italia 11
EG - Egitto 10
PE - Perù 9
PK - Pakistan 9
BA - Bosnia-Erzegovina 8
UZ - Uzbekistan 8
NP - Nepal 7
VE - Venezuela 7
AZ - Azerbaigian 6
EU - Europa 6
KZ - Kazakistan 6
KW - Kuwait 5
UY - Uruguay 5
AE - Emirati Arabi Uniti 4
DO - Repubblica Dominicana 4
IL - Israele 4
KE - Kenya 4
SA - Arabia Saudita 4
AU - Australia 3
BY - Bielorussia 3
HN - Honduras 3
LT - Lituania 3
MD - Moldavia 3
NG - Nigeria 3
PT - Portogallo 3
SY - Repubblica araba siriana 3
TN - Tunisia 3
BG - Bulgaria 2
CH - Svizzera 2
CM - Camerun 2
CZ - Repubblica Ceca 2
GY - Guiana 2
HR - Croazia 2
KG - Kirghizistan 2
PS - Palestinian Territory 2
RO - Romania 2
RS - Serbia 2
A1 - Anonimo 1
AL - Albania 1
AO - Angola 1
BB - Barbados 1
BO - Bolivia 1
BW - Botswana 1
CR - Costa Rica 1
ET - Etiopia 1
GT - Guatemala 1
HU - Ungheria 1
JM - Giamaica 1
JO - Giordania 1
KH - Cambogia 1
MN - Mongolia 1
MR - Mauritania 1
MU - Mauritius 1
NO - Norvegia 1
OM - Oman 1
PA - Panama 1
SN - Senegal 1
TG - Togo 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
Totale 15.840
Salva come PNG Salva come JPEG
Città #
Jacksonville 794
Fairfield 742
Ashburn 735
Dallas 632
Singapore 604
Chandler 537
Dublin 452
Boardman 421
Wilmington 315
Woodbridge 303
Hong Kong 257
Seattle 256
Houston 250
Des Moines 242
Cambridge 241
New York 235
Ann Arbor 193
Lawrence 173
Princeton 173
San Mateo 172
Ho Chi Minh City 127
The Dalles 114
Moscow 108
Turin 103
San Diego 98
Beijing 97
Los Angeles 97
Abidjan 95
Hefei 88
Munich 87
São Paulo 61
Hanoi 57
Centro 51
Buffalo 46
Redmond 41
Chicago 40
London 38
Rio de Janeiro 27
Turku 26
Helsinki 25
Ancona 23
Brooklyn 23
Shanghai 23
Columbus 21
Da Nang 21
Nuremberg 21
Johannesburg 18
Norwalk 18
Washington 18
Montreal 17
Haiphong 16
Marche 16
Ottawa 16
Warsaw 15
Brussels 14
Guangzhou 14
Tokyo 14
Belo Horizonte 13
Biên Hòa 13
Kilburn 13
Quito 13
Salt Lake City 13
Santa Clara 13
Atlanta 12
Boston 12
Brasília 12
Curitiba 12
Guayaquil 12
Milan 12
Ninh Bình 12
Pune 12
Stockholm 12
Wuhan 12
Council Bluffs 11
Porto Alegre 11
Ankara 10
Asunción 10
Bologna 9
Chennai 9
Denver 9
Poplar 9
Rome 9
Tampa 9
Amsterdam 8
Betim 8
Campinas 8
Fortaleza 8
Izmir 8
Recife 8
San Francisco 8
Tashkent 8
Bari 7
Goiânia 7
Jakarta 7
Manaus 7
Manchester 7
Mexico City 7
Seoul 7
Contagem 6
Dhaka 6
Totale 9.880
Salva come PNG Salva come JPEG
Nome #
Antimicrobial Resistance: A Challenge for the Future 263
Activity of nitazoxanide alone and in combination with azithromycin and rifabutin against Cryptosporidium parvum in cell culture. 173
Candida guilliermondii fungemia in patients with hematologic malignancies. 161
An (Italian) proposal for a comprehensive approach to infections across the surgical pathway 159
Activity of buforin II alone and in combination with azithromycin and minocycline against Cryptosporidium parvum in cell culture. 156
Invasive Aspergillosis in liver transplant recipients: Epidemiology, clinical characteristics, treatment, and outcomes in 116 cases 152
Antimicrobial activity of polycationic peptides 147
Anidulafungin in combination with amphotericin B against Aspergillus fumigatus. 142
Delay of antifungal therapy influences the outcome of invasive aspergillosis in experimental models of infection 141
ACTIVITY OF THE NEW ANTIFUNGAL TRIAZOLE, POSACONAZOLE, AGAINST CRYPTOCOCCUS NEOFORMANS 137
Carbapenem-Resistant Klebsiella pneumoniae influences the outcome of early infections in liver transplant recipients 137
Epidemiology and outcome of systemic infections due to saprochaete capitata: case report and review of the literature 136
Analysis of antibody response to Cryptococcus neoformans in five patients with AIDS and cryptococcosis by immunoblotting. 130
Epidemiology, clinical characteristics, and outcome of candidemia in a tertiary referral center in Italy from 2010 to 2014 130
Anticryptosporidial activity of ranalexin, lasalocid and azithromycin alone and in combination in cell lines. 126
Characterisation of candidemia in patients with recent surgery: A 7-year experience 126
Species distribution and antifungal susceptibilities of bloodstream Candida isolates: a nine-years single center survey 124
Candidemia in intensive care units over nine years at a large Italian university hospital: Comparison with other wards 122
Comparison of liver fibrosis progression in HIV/HCV co-infected and HCV mono-infected patients by transient elastometry 121
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial 121
Multicentre validation of a EUCAST method for the antifungal susceptibility testing of microconidia-forming dermatophytes 121
Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU 120
Heterozygosis and pathogenicity of Cryptococcus neoformans AD-hybrid isolates. 119
In-vitro effect of short-term exposure to two synthetic peptides, alone or in combination with clarithromycin or rifabutin, on Cryptosporidium parvum infectivity. 118
Trichosporon beigelii fungaemia in an AIDS patient. 117
Changing characteristics and risk factors of patients with and without incident HCV infection among HIV-infected individuals 116
Prevalence and predictors of malignancies in a polycentric cohort of HIV patients from Italy 116
High rate of ceftobiprole resistance among clinical methicillin-resistant Staphylococcus aureus isolates from a hospital in central Italy 115
Acute histoplasmosis in immunocompetent travelers: a systematic review of literature 114
Effects of caspofungin against Candida guilliermondii and Candida parapsilosis. 113
Bloodstream infections in the COVID-19 era: results from an Italian multi-centre study 113
Ceftazidime-Avibactam for the Treatment of Multidrug-Resistant Pathogens: A Retrospective, Single Center Study 113
Anticryptosporidial activity of cationic peptides alone and in combination with inhibitors of ion transport systems. 112
Comparison of three methods for testing azole susceptibilities of Candida albicans strains isolated sequentially from the oral cavities of aids patients. 111
In-vitro activity of the synthetic protegrin IB-367 alone and in combination with antifungal agents against clinical isolates of Candida spp. 111
Evaluating Liver Fibrosis by Transient Elastometry in Patients With HIV-HCV Coinfection and Monoinfection. 111
Aspergillus spp invasive external otitis: favourable outcome with a medical approach 110
Candidemia in the elderly: What does it change? 109
Sequential therapy with caspofungin and fluconazole for Candida albicans infection. 106
Clinical and epidemiological characteristics of KPC-producing Klebsiella pneumoniae from bloodstream infections in a tertiary referral center in Italy 106
Statistical analyses of correlation between fluconazole MICs for Candida spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2). 105
Comparison of visual 24-hour and spectrophotometric 48-hour MICs to CLSI reference microdilution MICs of fluconazole, itraconazole, posaconazole, and voriconazole for Candida spp.: a collaborative study. 105
Epidemiology and microbiology of surgical wound infections. 105
EUCAST technical note on posaconazole. 105
Factors related to outcome of bloodstream infections due to Candida parapsilosis complex 105
Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole. 102
Antifungal susceptibility patterns of yeast isolates causing bloodstream infections. 101
Osteomyelitis caused by Aspergillusspecies: a review of 310 reported cases 100
Effects of amphotericin B on Aspergillus flavus clinical isolates with variable susceptibilities to the polyene in an experimental model of systemic aspergillosis. 99
Reply to Ma et al.: Osteomyelitis caused by aspergillus species 99
Candidemia in Internal Medicine: Facing the New Challenge 99
Central venous catheter unrelated candidemia influences the outcome of infection in patients with solid tumors 98
In vitro activities of voriconazole in combination with other three antifungal agents against Candida glabrata 97
In vitro activity of the protegrin IB-367 alone and in combination compared with conventional antifungal agents against dermatophytes 97
A comparative analysis of unintegrated HIV-1 DNA measurement as a potential biomarker of the cellular reservoir in the blood of patients controlling and non-controlling viral replication 97
In-vitro activity of rifabutin and albendazolo singly and in combination with other clinically used antimicrobial agents against Pneumocystis carinii. 96
Experimental induction of fluconazole resistance in Candida tropicalis ATCC 750. 95
Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital. 95
Turbidimetric and visual criteria for determining the in vitro activity of six antifungal agents against Candida spp. and Cryptococcus neoformans. 95
In-vitro activity of five antifungal agents against uncommon clinical isolates of Candida spp. 94
In vitro activity of the lipopeptide derivative (Pal-Lys-Lys-NH), alone and in combination with antifungal agents, against clinical isolates of dermatophytes. 94
Comparative Effects of Micafungin, Caspofungin, and Anidulafungin against a Difficult-To-Treat Fungal Opportunistic Pathogen, Candida glabrata 94
Clinical efficacy and tolerability of caspofungin in a renal transplant patient with Aspergillus flavus lung infection: case report. 94
Evaluation of the disk diffusion method compared to the microdilution method in susceptibility testing of anidulafungin against filamentous fungi. 92
EUCAST Technical Note on voriconazole. 91
EUCAST technical note on Amphotericin B 91
In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azoles. 91
In vitro activity of the synthetic lipopeptide PAL-Lys-Lys-NH(2) alone and in combination with antifungal agents against clinical isolates of Cryptococcus neoformans. 90
In vitro activities of membrane-active peptides alone and in combination with clinically used antimicrobial agents against Stenotrophomonas maltophilia. 90
Antifungal combinations in dermatophytes 90
Antifungal Combinations against Candida Species: From Bench to Bedside 89
In vitro activities of voriconazole in combination with three other antifungal agents against Candida glabrata. 89
EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. 89
Comparison of the fungicidal activities of caspofungin and amphotericin B against Candida glabrata. 89
How to: EUCAST recommendations on the screening procedure E.Def 10.1 for the detection of azole resistance in Aspergillus fumigatus isolates using four-well azole-containing agar plates 89
Comparison of four methods for DNA typing of clinical isolates of Candida glabrata. 88
In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens 87
Voriconazole and multidrug resistance in Candida albicans. 87
Comparison between disk diffusion and microdilution methods for determining susceptibility of clinical fungal isolates to caspofungin. 87
Infection due to Absidia corymbifera in a patient with a massive crush trauma of the foot 87
Caspofungin in combination with amphotericin B against Candida glabrata. 87
EUCAST technical note on fluconazole. 87
Tolerance to amphotericin B in clinical isolates of Candida tropicalis. 87
Epidemiology of onychomycosis and paronychia in the area of ANCONA (ITALY) over a period of 5 years 86
In vitro and in vivo effects of echinocandins against Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis. 86
Caspofungin in combination with amphotericin B against Candida parapsilosis. 86
Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. 86
In vitro and in vivo activities of posaconazole against zygomycetes with various degrees of susceptibility. 86
In vitro activity of Tachyplesin III alone and in combination with terbinafine against clinical isolates of dermatophytes. 86
Prevalence and predictors of malignancies in HIV patients: results of a retrospective multicentric Italian cohort. 86
Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-CoV-2 infection: a multicentre cohort study (PREDI-CO study) 86
Treatment of murine cryptococcal meningitis with UR-9751 and UR-9746. 85
ELECTROPHORETIC KARYOTYPING AND TRIAZOLE SUSCEPTIBILITY OF CANDIDA GLABRATA CLINICAL ISOLATES 84
Electrophoretic karyotyping and antifungal susceptibility patterns of Candida parapsilosis clinical isolates causing deep and superficial fungal infections 84
In vitro susceptibility of dermatophytes to conventional and alternative antifungal agents. 84
In-vitro activity of polycationic peptides against Cryptosporidium parvum, Pneumocystis carinii and yeast clinical isolates. 82
Italian guidelines for diagnosis, prevention, and treatment of invasive fungal infections in solid organ transplant recipients. 82
SIMIFF study: Italian fungal registry of mold infections in hematological and non-hematological patients. 82
Efficacy of caspofungin against Aspergillus terreus 82
Molecular epidemiology of Italian clinical Cryptococcus neoformans var. grubii isolates 82
Totale 10.658
Salva come PNG Salva come JPEG
Categoria #
all - tutte 84.356
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 84.356
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.505 0 0 0 0 0 190 253 159 223 283 289 108
2021/20221.519 133 433 13 42 20 63 117 70 76 136 156 260
2022/20232.071 215 172 150 113 135 354 13 96 563 11 176 73
2023/20241.297 214 25 68 240 248 280 26 18 15 14 15 134
2024/20252.350 212 203 166 29 61 60 168 112 609 161 238 331
2025/20263.735 414 589 765 1.144 668 155 0 0 0 0 0 0
Totale 16.071